Guidelines for the Management of Patients with Alopecia Areata in Korea: Part I Topical and Device-based Treatment

Park, Hyun Sun; Kim, Jung Eun; Choi, Jee Woong; Kim, Doyoung; Jang, Yo-Soon; Lee, Young; Jeon, Jiehyun; Shin, Hyun-Tae; Kim, Min Sung; Shin, Jung Won; Cho, Sung Bin; Lew, Bark Lynn; Choi, Gwang‐Seong

doi:10.5021/ad.22.168

Cited by 3 publications

(2 citation statements)

References 169 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AA shows very diverse clinical pictures for each patient. Therefore, an appropriate scaling system to determine severe AA is necessary to decide the patient’s prognosis and treatment response, as treatment differs according to the severity 3 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Korean Consensus Criteria for the Severity Classification of Alopecia Areata

Jang,

Lee,

Park

et al. 2024

Ann Dermatol

Self Cite

View full text Add to dashboard Cite

Background A set of criteria for severity classification is essential in alopecia areata (AA). Currently, no guidelines are universally accepted for defining AA severity. Objective This study aimed to establish a set of consensus criteria for classifying the severity of and identifying treatment refractoriness in AA. Methods A preliminary draft of the definition for moderate-to-severe AA was crafted based on available evidence, and members of the Korean Hair Research Society (KHRS) subsequently endorsed the recommendation through an online survey. Results In the first Delphi round, consensus was attained on 15 questions. After refining certain items in the second round, consensus was achieved on 23 out of 26 questions. The KHRS first defined AA severity using the severity of alopecia tool (SALT). SALT ≥50 was defined as severe, 20≤ SALT <50 as moderate, and SALT <20 as mild. Moderate AA was considered severe if it meets one or more of the following criteria: dermatology life quality index >10, presence of accompanying eyebrow or eyelash loss, positive hair loss activity, or treatment-refractory AA. Conclusion These consensus criteria can help clinicians accurately diagnose AA, provide appropriate treatment, and monitor its progression.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Standardized guidelines help dermatologists in assessing the extent and severity of AA. This information is crucial for making treatment decisions 2 3 . The severity of AA can significantly affect the choice of treatment.…”

Section: Introductionmentioning

confidence: 99%

Korean Consensus Criteria for the Severity Classification of Alopecia Areata

Jang,

Lee,

Park

et al. 2024

Ann Dermatol

Self Cite

View full text Add to dashboard Cite

show abstract

Treatment patterns and healthcare resource utilization among patients with alopecia areata: A real‐world chart review in South Korea

Kwon,

Wallace,

Messina

et al. 2024

The Journal of Dermatology

View full text Add to dashboard Cite

Alopecia areata (AA) is a clinically heterogeneous, immune‐mediated, non‐scarring hair loss disorder. This real‐world chart review sought to characterize treatment patterns and healthcare resource use among patients with severe AA in South Korea. A web‐based chart review of 40 dermatologists was conducted in which the medical charts of 151 adult patients diagnosed with severe AA between May 2019 and April 2021 were reviewed. Anonymized data on patient characteristics, treatment patterns, healthcare resource use, and clinical outcomes were extracted from the date of severe disease diagnosis until the date of data collection (September–November 2022). Sixty‐six percent of patients were diagnosed with severe disease at initial presentation, while 34% were re‐classed to severe during the disease course. Mean estimated patient age at the time of diagnosis of severe AA was 37.1 (range 22–68) years. Fifty‐three percent of patients were male. Most patients (93.4%) received pharmacological treatment for their condition; 45.5% received ≥2 lines of treatment with a mean duration of 24 months. First‐line treatment discontinuation due to lack of efficacy occurred in 46.0% of cases. Hair regrowth occurred in 71.0% of patients, 59.2% of whom experienced major regrowth (≥60%) during the follow‐up period. Median (95% confidence interval) time to regrowth was 13.7 (11.0–20.6) months. Treatment visit rates per person‐year ranged from two (phototherapy) to 10 (topical treatment), dermatologist visits occurred at a rate of 12.9 per person‐year and 6.0% of patients were hospitalized due to alopecia areata. The majority of hospitalizations were related to treatment and occurred in patients who received pulse systemic corticosteroid therapy. The patient and economic burden of AA in South Korea is high and there remains a critical unmet need among patients with severe AA with respect to the effectiveness of commonly used treatment strategies.

show abstract